IRLAB Therapeutics AB (FRA:6IRA) Ending Cash Position : €7.96 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is IRLAB Therapeutics AB Ending Cash Position?

IRLAB Therapeutics AB's Ending Cash Position for the quarter that ended in Sep. 2024 was €7.96 Mil.

IRLAB Therapeutics AB's quarterly Ending Cash Position increased from Mar. 2024 (€6.46 Mil) to Jun. 2024 (€8.71 Mil) but then declined from Jun. 2024 (€8.71 Mil) to Sep. 2024 (€7.96 Mil).

IRLAB Therapeutics AB's annual Ending Cash Position declined from Dec. 2021 (€39.13 Mil) to Dec. 2022 (€22.99 Mil) and declined from Dec. 2022 (€22.99 Mil) to Dec. 2023 (€9.95 Mil).

IRLAB Therapeutics AB Ending Cash Position Historical Data

The historical data trend for IRLAB Therapeutics AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Ending Cash Position Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

10.55

27.23

39.13

22.99

9.95

IRLAB Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															10.04	9.95	6.46	8.71	7.96

IRLAB Therapeutics AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

IRLAB Therapeutics AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	22.597	+	-12.646
	=	9.95

IRLAB Therapeutics AB's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	8.638	+	-0.677
	=	7.96

IRLAB Therapeutics AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (FRA:6IRA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

IRLAB A:Sweden

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines